HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Corcept Therapeutics (NASDAQ:CORT) and maintained a $40 price target.
May 29, 2024 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Corcept Therapeutics and maintained a $40 price target, indicating continued confidence in the company's stock performance.
The reiteration of a Buy rating and maintenance of a $40 price target by HC Wainwright & Co. suggests strong confidence in Corcept Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100